Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study
Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study
复制标题
DOI：
10.1093/ecco-jcc/jjaa205
复制
发表时间：
2021-04-01
影响因子：
8
通讯作者：
Burisch, Johan
中科院分区：
文献类型：
--
作者：
Attauabi, Mohamed;Poulsen, Anja;Burisch, Johan
背景和目标：由于没有基于人群的研究调查了炎症性肠病[IBD]患者对COVID-19的易感性和病程，我们的目的是在基于人群的环境中调查这一主题。首先，前瞻性随访了全国范围内所有确诊为COVID-19的IBD患者队列，以调查这两种疾病的病程。其次，在一个260万丹麦公民的人群队列中，我们确定了所有接受SARS-CoV-2检测的个体，以确定患有和不患有IBD和其他免疫介导的炎症性疾病[IMID]的患者中COVID-19的发生率。2020年1月28日至2020年6月2日期间，在全国队列中共确定了76名患有COVID-19的IBD患者，并进行了35天的前瞻性随访（四分位距[IQR]：25-51）。大部分患者[n = 19：25%]需要COVID-19相关住院7天[IQR：2-8.5]与65岁或以上相关（比值比[OR] = 23].80，95%置信区间[CI] 6.32-89.63，p < 0.01）和存在任何非IMID合并症[OR=8.12，95% CI 2.55-25.87，p < 0.01]，但未使用免疫调节剂[p = 0.52]或生物疗法[p = 0.14]。在基于人群的研究中，231601名居民中有8476人（3.7%）检测出SARS-CoV-2阳性;然而，IBD患者[2486例患者中的62例= 2.5%，p < 0.01]和其他IMID患者[16492例患者中的531例= 3.2%，结论：患有IMID（包括IBD）的患者对COVID-19的易感性显著低于未患有IMID的患者，免疫抑制治疗和IBD活动均与COVID-19的病程无关。
Background and Aims: As no population-based study has investigated the susceptibility and disease course of COVID-19 among patients with inflammatory bowel diseases [IBD], we aimed to investigate this topic in a population-based setting.Methods: Two cohorts were investigated. First, a nationwide cohort of all IBD patients diagnosed with COVID-19 was prospectively followed to investigate the disease courses of both diseases. Second, within a population-based cohort of 2.6 million Danish citizens, we identified all individuals tested for SARS-CoV-2 to determine the occurrence of COVID-19 among patients with and without IBD and other immune-mediated inflammatory diseases [IMIDs].Results: Between January 28, 2020 and June 2, 2020, a total of 76 IBD patients with COVID-19 were identified in the national cohort and prospectively followed for 35 days (interquartile range [IQR]: 25-51). A large proportion [n = 19: 25%] required a COVID-19-related hospitalisation for 7 days [IQR: 2-8.5] which was associated with being 65 years or older (odds ratio [OR] = 23].80, 95% confidence interval [CI] 6.32-89.63, p < 0.01) and presence of any non-IMID comorbidity [OR=8.12, 95% CI 2.55-25.87, p < 0.01], but not use of immunomodulators [p = 0.52] or biologic therapies [p = 0.14]. In the population-based study, 8476 of 231 601 [3.7%] residents tested positive for SARS-CoV-2; however, the occurrence was significantly lower among patients with IBD [62 of the 2486 patients = 2.5%, p < 0.01] and other IMIDs [531 of 16 492 patients = 3.2%, p < 0.01] as compared with patients without IMIDs.Conclusions: Patients with IMIDs, including IBD, had a significantly lower susceptibility to COVID-19 than patients without IMIDs, and neither immunosuppressive therapies nor IBD activity were associated with the disease course of COVID-19.